About Gamma-aminobutyric acid receptor subunit alpha-2
Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) is a protein
from Homo sapiens identified by UniProt accession
P47869, 451 residues long.
MolForge cross-references it against 0 known binders and
383 disease associations.
Target properties
| Protein name | Gamma-aminobutyric acid receptor subunit alpha-2 |
| UniProt accession | P47869 |
| Gene | GABRA2 |
| Organism | Homo sapiens |
| Length | 451 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (383)
Diseases linked to this target (Open Targets).
- alcohol dependence · score 0.69
- unipolar depression · score 0.61
- insomnia · score 0.61
- epilepsy · score 0.61
- anxiety · score 0.60
- Agitation · score 0.60
- panic disorder · score 0.60
- pain · score 0.60
- anxiety disorder · score 0.60
- delirium · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P47869-F1 | alphafold | PREDICTED | 83.27 | — |
Amino-acid sequence (451 residues)
MKTKLNIYNM QFLLFVFLVW DPARLVLANI QEDEAKNNIT IFTRILDRLL DGYDNRLRPG LGDSITEVFT NIYVTSFGPV SDTDMEYTID VFFRQKWKDE RLKFKGPMNI LRLNNLMASK IWTPDTFFHN GKKSVAHNMT MPNKLLRIQD DGTLLYTMRL TVQAECPMHL EDFPMDAHSC PLKFGSYAYT TSEVTYIWTY NASDSVQVAP DGSRLNQYDL LGQSIGKETI KSSTGEYTVM TAHFHLKRKI GYFVIQTYLP CIMTVILSQV SFWLNRESVP ARTVFGVTTV LTMTTLSISA RNSLPKVAYA TAMDWFIAVC YAFVFSALIE FATVNYFTKR GWAWDGKSVV NDKKKEKASV MIQNNAYAVA VANYAPNLSK DPVLSTISKS ATTPEPNKKP ENKPAEAKKT FNSVSKIDRM SRIVFPVLFG TFNLVYWATY LNREPVLGVS P
Explore Gamma-aminobutyric acid receptor subunit alpha-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets